Warburg O. On the origine of the cancer cells. Science 1956; 123: 309-14.
Gallagher BM, Fowler JS, Gutterson NI, et al. Metabolic trapping as a principle of radiopharmaceutical design: Some factors responsive for the biodistribution of (18F) 2-deoxy-2-fluoro-D-glucose. J Nucl Med 1978; 19: 1154-61.
Rigo P, Paulus P, Kaschten BJ, et al. Oncological applications of positron emission tomography with fluorine-18-flurorodeoxyglucose. Eur J Nucl Med 1996; 23: 1641-74.
Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using (18F)-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations. Eur J Cancer 1999; 13: 1773-82.
Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol 1998; 6: 931-3.
Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-Body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical tomography scan imaging. Blood 1999; 94: 429-33.
Hoekstra OS, Ossenkoppele GJ, Golding R, et al. Early treatment response in malignant lymphoma, as determined by planar flourine-18-flourodeoxyglucose scintigraphy. J Nucl Med 1993; 34: 1706-10.
Dimitrakopoulou-Strauss A, Strauss LS, Goldschmidt H, et al. Evaluation of tumor metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur J Nucl Med 1995; 22: 434-42.
Römer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose. Blood 1998; 91: 4464-71.
Jerusalem G, Beguin Y, Fassotte MF, et al. Persistent tumoral 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma (NHL). Haematologica 2000 (in press).
Wahl RL, Zasadny K, Helvie M, et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation. J Clin Oncol 1993; 11: 2101-11.
Jansson T, Westlin JE, Ahlstrom H, et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation? J Clin Oncol 1995; 13: 1470-7.
Smith IC, Welch AE, Hutcheon AW, et al. Positron emission tomography using (18F)-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000; 18: 1676-88.
Schelling M, Avril N, Nährig J, et al. Positron emission tomography using (18F) fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000; 18: 1689-95.
